Understand the source comparison
Best Peptides for PCOS Researchers: Peptide Comparison
Before selecting a peptide for PCOS research, match the mechanism to your model's primary phenotype. Insulin resistance, inflammation, or combined metabolic-reproductive dysregulation. Each peptide addresses different pathways, and choosing incorrectly adds co
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide for PCOS research, match the mechanism to your model's primary phenotype. Insulin resistance, inflammation, or combined metabolic-reproductive dysregulation. Each peptide addresses different pathways, and choosing incorrectly adds confounding variables that obscure mechanistic interpretation.
- Tirzepatide
- Dual GIP/GLP-1 agonist
- Weekly (5-day half-life)
- Reduces fasting insulin 30–35%, improves insulin sensitivity
- Reduces free testosterone 25–30%, restores cycle regularity in 60–70%
- Insulin-driven hyperandrogenism models
- Semaglutide
- GLP-1 receptor agonist
- Weekly (168-hour half-life)
- Reduces fasting insulin 22–34%, enhances glucose-dependent insulin secretion
- Improves ovulatory frequency, modest androgen reduction
- Mechanistic GLP-1 pathway studies, anovulation models
- BPC-157
- Anti-inflammatory, tissue repair
- Daily (4-hour half-life)
- Minimal direct metabolic effect
- Reduces ovarian cyst formation 40–45%, restores cyclicity in inflammatory models
- Inflammation-mediated ovarian dysfunction, oxidative stress models